Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
The investment will accelerate the overall Sarclisa development program
Subscribe To Our Newsletter & Stay Updated
